TY - JOUR
T1 - Prognostic Significance of the Number and Extent of Metastatic Lymph Nodes in Patients with Esophageal Cancer
T2 - Comparison of the Union for International Cancer Control 8th Edition and Japan Esophageal Society Japanese Classification of Esophageal Cancer 11th Edition Classifications for Esophageal Cancer
AU - Ozawa, Hiroki
AU - Kawakubo, Hirofumi
AU - Takeuchi, Masashi
AU - Ishibashi, Yoshiki
AU - Matsuda, Satoru
AU - Mayanagi, Shuhei
AU - Takemura, Ryo
AU - Irino, Tomoyuki
AU - Fukuda, Kazumasa
AU - Nakamura, Rieko
AU - Wada, Norihito
AU - Kitagawa, Yuko
N1 - Funding Information:
The authors thank Kumiko Motooka, Department of Surgery, Keio University School of Medicine, and Doruk Orgun, for their help in the preparation of this report.
Funding Information:
Kazumasa Fukuda belongs to the Keio University School of Medicine Endowed Chair in Cancer Research (funded by Chugai Pharmaceutical Co., Ltd and Taiho Pharmaceutical Co., Ltd). Yuko Kitagawa has relevant financial activities outside the submitted work with the following companies: Taiho Pharmaceutical Co., Ltd; Chugai Pharmaceutical Co., Ltd; Yakult Honsha Co. Ltd; Daiichi Sankyo Company, Ltd; Merck Serono Co., Ltd; AsahiKasei Co., Ltd; EA Pharma Co., Ltd; Otsuka Pharmaceutical Co., Ltd; Takeda Pharmaceutical Co., Ltd; Otsuka Pharmaceutical Factory Inc.; Shionogi & Co., Ltd; Kaken Pharmaceutical Co., Ltd; Kowa Pharmaceutical Co., Ltd; Astellas Pharma Inc.; Medicon Inc.; Dainippon Sumitomo Pharma Co., Ltd; Taisho Toyama Pharmaceutical Co., Ltd; Kyouwa Hakkou Kirin Co., Ltd; Pfizer Japan Inc.; Ono Pharmaceutical Co., Ltd; Nihon Pharmaceutical Co., Ltd; Japan Blood Products Organization; Medtronic Japan Co., Ltd; and Sanofi K.K. He has also received grants from Eisai Co., Ltd; Tsumura & Co.; KCI Licensing, Inc.; Abbott Japan Co., Ltd; Fujifilm Toyama Chemical Co., Ltd; and Medicon Inc. Hiroki Ozawa, Hirofumi Kawakubo, Masashi Takeuchi, Yoshiki Ishibashi, Satoru Matsuda, Shuhei Mayanagi, Ryo Takemura, Tomoyuki Irino, Rieko Nakamura, and Norihito Wada have no disclosures to declare.
Publisher Copyright:
© 2021, Society of Surgical Oncology.
PY - 2021/10
Y1 - 2021/10
N2 - Background: The tumor, node, metastasis staging system of the Union for International Cancer Control (UICC) has been used worldwide for esophageal cancer, and, in Japan, the Japan Esophageal Society Japanese Classification of Esophageal Cancer (JES) has also been used; however, there is a big difference between the two classifications with regard to node staging. We hypothesized that these two node staging systems may lead to different outcome predictions in terms of tumor location. Methods: This study enrolled 409 patients who underwent esophagectomy at Keio University Hospital, Tokyo, Japan, between January 2005 and December 2017. We included those who underwent R0 or R1 resection or esophagectomy with additional organ excision, and excluded those who underwent salvage surgery. Thereafter, we investigated how the number or spread of metastatic lymph nodes affected the prognosis. Results: For all 409 patients, the 5-year overall survival rate was 64.1% and the 5-year recurrence-free survival rate was 58.4%. The concordance indices were 0.756 for UICC 8th edition pathological node staging and 0.732 for JES 11th edition pathological node staging (p = 0.06). Based on tumor location, the difference in the concordance indices between these two classifications was greatest for lower thoracic esophageal tumors (p = 0.02). Conclusions: For all patients, the UICC 8th edition node staging system tended to reflect survival more precisely than that of the JES 11th edition. For lower thoracic esophageal tumors in particular, the former node staging system could be more useful.
AB - Background: The tumor, node, metastasis staging system of the Union for International Cancer Control (UICC) has been used worldwide for esophageal cancer, and, in Japan, the Japan Esophageal Society Japanese Classification of Esophageal Cancer (JES) has also been used; however, there is a big difference between the two classifications with regard to node staging. We hypothesized that these two node staging systems may lead to different outcome predictions in terms of tumor location. Methods: This study enrolled 409 patients who underwent esophagectomy at Keio University Hospital, Tokyo, Japan, between January 2005 and December 2017. We included those who underwent R0 or R1 resection or esophagectomy with additional organ excision, and excluded those who underwent salvage surgery. Thereafter, we investigated how the number or spread of metastatic lymph nodes affected the prognosis. Results: For all 409 patients, the 5-year overall survival rate was 64.1% and the 5-year recurrence-free survival rate was 58.4%. The concordance indices were 0.756 for UICC 8th edition pathological node staging and 0.732 for JES 11th edition pathological node staging (p = 0.06). Based on tumor location, the difference in the concordance indices between these two classifications was greatest for lower thoracic esophageal tumors (p = 0.02). Conclusions: For all patients, the UICC 8th edition node staging system tended to reflect survival more precisely than that of the JES 11th edition. For lower thoracic esophageal tumors in particular, the former node staging system could be more useful.
UR - http://www.scopus.com/inward/record.url?scp=85102173933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102173933&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-09545-9
DO - 10.1245/s10434-020-09545-9
M3 - Article
C2 - 33748898
AN - SCOPUS:85102173933
SN - 1068-9265
VL - 28
SP - 6355
EP - 6363
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 11
ER -